Zacks Investment Research
10 Jul 2026, 22:51 UTC · 2h ago
CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
10 Jul 2026, 22:51 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
CRISPR Therapeutics AG is projected to report quarterly revenue of $7.42 million, representing a 733.26% increase year-over-year. — Triple-digit revenue growth is a strong fundamental signal for biotech companies in the scaling phase.
+0.60Analysts expect full-year revenue for CRISPR Therapeutics AG to reach $28.88 million, a 722.82% increase from the previous year. — Significant projected annual growth suggests a positive trajectory for the company's commercialization efforts.
+0.50CRSP shares declined 5.31% in the most recent session, underperforming both the S&P 500 and the Nasdaq. — Short-term price weakness and relative underperformance suggest a temporary loss of investor confidence.
-0.30Continue reading
6 related stories
Top 2 movers · tap to explore
CRISPR Therapeutics AG currently holds a Zacks Rank of #3 (Hold). — A 'Hold' rating indicates a neutral outlook, suggesting no immediate strong buy or sell catalyst.
+0.00Which stocks this story touches
The company shows significant expected year-over-year revenue growth and a monthly stock appreciation of 12.16%, despite a recent single-day dip.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2h ago
